These findings computationally nominate TIMP1 as a multi-cancer therapeutic target, with the identified small-molecule inhibitors warranting preclinical evaluation for targeted therapy development in CRC and other TIMP1-driven malignancies. This evidence concerns the gene TIMP1 and colorectal carcinoma.